These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9762353)

  • 21. Theoretical and experimental approaches to design effective antisense oligonucleotides.
    Sczakiel G
    Front Biosci; 2000 Jan; 5():D194-201. PubMed ID: 10702382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic agents.
    Gryaznov SM
    Biochim Biophys Acta; 1999 Dec; 1489(1):131-40. PubMed ID: 10807003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Properties of nicked and circular dumbbell RNA-DNA chimeric oligonucleotides.
    Yamakawa H; Hosono K; Ishibashi T; Takai K; Takaku H
    Nucleic Acids Symp Ser; 1995; (34):133-4. PubMed ID: 8841588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structures of DNA:DNA and DNA:RNA duplexes containing 5-(N-aminohexyl)carbamoyl-modified uracils reveal the basis for properties as antigene and antisense molecules.
    Juan EC; Kondo J; Kurihara T; Ito T; Ueno Y; Matsuda A; Takénaka A
    Nucleic Acids Res; 2007; 35(6):1969-77. PubMed ID: 17341465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic oligonucleotides for biomedical applications.
    Seliger H; Fröhlich A; Gröger G; Krist B; Montenarh M; Rösch H; Rösch R; Ortigao FR
    Nucleic Acids Symp Ser; 1991; (24):193-6. PubMed ID: 1726743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany.
    Uhlmann E
    Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ENA oligonucleotides as therapeutics.
    Koizumi M
    Curr Opin Mol Ther; 2006 Apr; 8(2):144-9. PubMed ID: 16610767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NMR solution structure of a parallel LNA quadruplex.
    Randazzo A; Esposito V; Ohlenschläger O; Ramachandran R; Mayola L
    Nucleic Acids Res; 2004; 32(10):3083-92. PubMed ID: 15181173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation.
    Manoharan M
    Biochim Biophys Acta; 1999 Dec; 1489(1):117-30. PubMed ID: 10807002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to degradation by nucleases of (2'S)-2'-deoxy-2'-C-methyloligonucleotides, novel potential antisense probes.
    Iribarren AM; Cicero DO; Neuner PJ
    Antisense Res Dev; 1994; 4(2):95-8. PubMed ID: 7950305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformationally restricted carbohydrate-modified nucleic acids and antisense technology.
    Herdewijn P
    Biochim Biophys Acta; 1999 Dec; 1489(1):167-79. PubMed ID: 10807006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligonucleotide charge reversal: 2'-O-lysylaminohexyl modified oligonucleotides.
    Winkler J; Noe CR
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):939-42. PubMed ID: 18058513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and properties of 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides.
    Morita K; Takagi M; Hasegawa C; Kaneko M; Tsutsumi S; Sone J; Ishikawa T; Imanishi T; Koizumi M
    Bioorg Med Chem; 2003 May; 11(10):2211-26. PubMed ID: 12713831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oligonucleotides and oligonucleotide conjugates: a new approach for cancer treatment.
    Da Ros T; Spalluto G; Prato M; Saison-Behmoaras T; Boutorine A; Cacciari B
    Curr Med Chem; 2005; 12(1):71-88. PubMed ID: 15638731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular dynamics simulation and binding energy calculation for estimation of oligonucleotide duplex thermostability in RNA-based therapeutics.
    Shen L; Johnson TL; Clugston S; Huang H; Butenhof KJ; Stanton RV
    J Chem Inf Model; 2011 Aug; 51(8):1957-65. PubMed ID: 21702481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Computer aid design of antisense oligonucleotide in gene therapy--review].
    Wu QW; Wu JJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):387-91. PubMed ID: 15228675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleic acid recognition. Marriage of convenience.
    Patel DJ
    Nature; 1993 Oct; 365(6446):490-2. PubMed ID: 8413600
    [No Abstract]   [Full Text] [Related]  

  • 39. Triple helix formation and the antigene strategy for sequence-specific control of gene expression.
    Praseuth D; Guieysse AL; Hélène C
    Biochim Biophys Acta; 1999 Dec; 1489(1):181-206. PubMed ID: 10807007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequence-specific artificial ribonucleases. I. Bis-imidazole-containing oligonucleotide conjugates prepared using precursor-based strategy.
    Beloglazova NG; Fabani MM; Zenkova MA; Bichenkova EV; Polushin NN; Sil'nikov VV; Douglas KT; Vlassov VV
    Nucleic Acids Res; 2004; 32(13):3887-97. PubMed ID: 15273275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.